SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Evofem
Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage
biopharmaceutical company, announced today that Chief Executive
Officer Saundra Pelletier will
present at two upcoming healthcare equity conferences:
- Stifel's 2019 Healthcare Conference on Wednesday, November 20, 2019 at 8:35 am EST in New
York, NY.
- Piper Jaffray's 31st Annual
Healthcare Conference on Wednesday,
December 4, 2019 at 9:30 am
EST in New York, NY.
Both conferences will be held at the Lotte New York Palace
Hotel. To access the live and archived webcasts of either event,
visit the Investors section of the Evofem Biosciences website at
www.evofem.com.
About Evofem Biosciences
Evofem Biosciences, Inc. is a
clinical-stage biopharmaceutical company committed to developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health. Evofem Biosciences aims to
advance the lives of women by developing novel solutions, such as
woman-controlled contraception and potential protection from
certain sexually transmitted infections. The Company is
leveraging its proprietary Multipurpose Vaginal pH Regulator
(MVP-R™) platform to develop Amphora® (L-lactic acid, citric
acid and potassium bitartrate) for hormone-free birth control and
prevention of chlamydia. For more information, please
visit www.evofem.com.
About Amphora
Amphora is an investigational MVP-R™
designed to regulate vaginal pH within the normal range of 3.5 to
4.5. This maintains an acidic environment which is inhospitable to
sperm as well as certain viral and bacterial pathogens associated
with sexually transmitted infections but is integral to the
survival of healthy bacteria in the vagina. Amphora met the
pre-specified primary endpoint of the Phase 3 AMPOWER trial,
demonstrated a favorable safety profile and was well tolerated. The
Company plans to resubmit the Amphora New Drug Application (NDA) in
the fourth quarter of 2019.
The Company expects to report top-line data in November 2019 from AMPREVENCE, the double-blinded
placebo-controlled Phase 2b clinical trial of Amphora to
prevent urogenital acquisition of Chlamydia trachomatis
and Neisseria gonorrhea (primary and secondary
endpoints, respectively) in women. There are currently no
therapeutics approved for the prevention of either STI.
Amphora® is a registered trademark and MVP-R™ is a
trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements related to the timing of the planned NDA
Amphora resubmission for prevention of pregnancy, potential FDA
approval of Amphora, and the potential commercial launch of
Amphora, and the timing and anticipated results of the
Phase 2b clinical trial of Amphora to prevent urogenital
acquisition of Chlamydia
trachomatis and Neisseria gonorrhea in
women. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
those, express or implied, in these forward-looking statements.
Important factors that could impair the value of Evofem
Biosciences' assets and business are disclosed in the risk factors
contained in its Annual Report on Form 10-K filed with
the Securities and Exchange Commission and subsequent
filings. All forward-looking statements are expressly qualified in
their entirety by such factors. Evofem Biosciences does not
undertake any duty to update any forward-looking statement except
as required by law.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
M: (917) 673-5775
Media Contact
Cara
Miller
Evofem Biosciences, Inc.
cmiller@evofem.com
O: (858) 550-1900 x272
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-upcoming-investor-conferences-300957841.html
SOURCE Evofem Biosciences, Inc.